Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Jupid | $840,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Manifest OS | $60,000,000 | (May 1, 2026)
Iterative Health | $77,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
BioOrbit | $13,334,811 | (May 1, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)